First North


Health Care

Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.



Länk till dynamisk (zoombar) graf för större skärmar

Nuvarande och kommande formation

MA Rank

Rulla till toppen